A combination of humanised anti-CD19 and anti-BCMA CAR T cells in patients with relapsed or refractory multiple myeloma: a single-arm, phase 2 trial-Reference-Cited by-同舟云学术

A combination of humanised anti-CD19 and anti-BCMA CAR T cells in patients with relapsed or refractory multiple myeloma: a single-arm, phase 2 trial

Published:2019-10 Issue:10 Volume:6 Page:e521-e529
ISSN:2352-3026
Container-title:The Lancet Haematology
language:en
Short-container-title:The Lancet Haematology

Author:

Yan Zhiling,Cao Jiang,Cheng Hai,Qiao Jianlin,Zhang Huanxin,Wang Ying,Shi Ming,Lan Jianping,Fei Xiaoming,Jin Lai,Jing Guangjun,Sang Wei,Zhu Feng,Chen Wei,Wu Qingyun,Yao Yao,Wang Gang,Zhao Jing,Zheng Junnian,Li Zhenyu,Xu Kailin

Funder

National Natural Science Foundation of China

Natural Science Foundation of Jiangsu Province

Key Research & Development Plan of Jiangsu Province

Jiangsu Province

China Postdoctoral Science Foundation

Jiangsu Provincial Key Medical Discipline, and The Project of Invigorating Health Care Through Science, Technology, and Education

Publisher

Elsevier BV

Subject

Hematology

Reference30 articles.

1. A phase 2 study of bortezomib in relapsed, refractory myeloma;Richardson;N Engl J Med,2003

2. Lenalidomide and venous thrombosis in multiple myeloma;Rajkumar;N Engl J Med,2006

3. Daratumumab, bortezomib, and dexamethasone for multiple myeloma;Palumbo;N Engl J Med,2016

4. Chimeric antigen receptor T cells for sustained remissions in leukemia;Maude;N Engl J Med,2014

5. Eradication of B-lineage cells and regression of lymphoma in a patient treated with autologous T cells genetically engineered to recognize CD19;Kochenderfer;Blood,2010

Cited by 234 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Chimeric antigen receptor T-cells: a review on current status and future directions for relapsed/refractory multiple myeloma;Frontiers in Oncology;2024-08-08

2. Comparing the Differences in Adverse Events among Chimeric Antigen Receptor T-Cell Therapies: A Real-World Pharmacovigilance Study;Pharmaceuticals;2024-08-05

3. Targeting cancer stem cells in multiple myeloma;Trends in Cancer;2024-08

4. Consensus guidelines and recommendations for the management and response assessment of chimeric antigen receptor T-cell therapy in clinical practice for relapsed and refractory multiple myeloma: a report from the International Myeloma Working Group Immunotherapy Committee;The Lancet Oncology;2024-08

5. Complex association of body mass index and outcomes in patients with relapsed and refractory multiple myeloma treated with CAR-T cell immunotherapy;Cytotherapy;2024-08